ProCE Banner Activity

LUX-Lung 7: Head-to-Head Comparison of Afatinib vs Gefitinib in Chemotherapy-Naive Patients With Advanced EGFR-Mutant NSCLC

Slideset Download
The efficacy benefit of afatinib was observed for all patient subgroups with advanced EGFR-mutant NSCLC, except for light exsmokers and patients without brain metastases, and did not differ by EGFR mutation type.

Released: June 28, 2016

Expiration: June 27, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Genentech Roche Virology

Lilly

Novartis Pharmaceuticals Corporation